Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

JP Mor­gan isn’t typ­i­cal­ly a da­ta con­fer­ence. But there are al­ways ex­cep­tions for da­ta that could make or break a com­pa­ny, piquing the in­ter­est of po­ten­tial in­vestors and part­ners alike.

Da­ta, for in­stance, like what Sekar Kathire­san is bring­ing to the vir­tu­al con­fer­ence, show­ing that a one-time treat­ment with Verve Ther­a­peu­tics’ base ed­i­tor can keep PC­SK9 lev­els low — there­by low­er­ing LDL cho­les­terol, aka the bad kind — out to 6 months. In non-hu­man pri­mates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER